Alamifovir

Alamifovir (LY582563; MCC-478), a purine nucleotide analogue proagent, shows potent activity against wild type and lamivudine resistant hepatitis B virus (HBV) . Alamifovir has high activity against HBV replication and sustained antiviral effect[1][2].

Product Specifications

CAS Number

[193681-12-8]

Product Name Alternative

LY582563; MCC-478

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

HBV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/alamifovir.html

Purity

95.0

Solubility

DMSO : 5.75 mg/mL (ultrasonic; warming)

Smiles

COC1=CC=C(C=C1)SC2=C3N=CN(C3=NC(N)=N2)CCOCP(OCC(F)(F)F)(OCC(F)(F)F)=O

Molecular Formula

C19H20F6N5O5PS

Molecular Weight

575.42

Precautions

H302, H315, H319

References & Citations

[1]Danny K W Soon, et al. Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection. J Hepatol. 2004 Nov;41 (5) :852-8.|[2]Suzane Kioko Ono-Nita, et al. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob Agents Chemother. 2002 Aug;46 (8) :2602-5.